Pharmacokinetics of valaciclovir

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 6, 2004, Pages 899-901

  MacDougall, Conan ^a   Guglielmo, B Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Absorption; Aciclovir; Bioavailability; Herpesviruses

Indexed keywords

ACICLOVIR; CARRIER PROTEIN; CEFALEXIN; ESTER; PEPTIDE TRANSPORTER 1; VALACICLOVIR; VALINE;

ARTICLE; CHEMICAL MODIFICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYDROLYSIS; ESTERIFICATION; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; LIVER; NONHUMAN; SMALL INTESTINE;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; BIOTRANSFORMATION; CARRIER PROTEINS; HUMANS; HYDROLYSIS; SYMPORTERS; VALINE;

EID: 3042588798     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh244     Document Type: Article

References (37)

1. Wagstaff, A., Faulds, D., & Goa, K. (1994). Aciclovir. Drugs 47, 153-205.
2. Beutner, K. (1995). Valaciclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Research 28, 281-90.
3. Rolan, P. (1995). Pharmacokinetics of new antiherpetic agents. Clinical Pharmacokinetics 29, 333-40.
4. Acosta, E., & Fletcher, C. (1997). Valaciclovir. Annals of Pharmacotherapy 31, 185-91.
5. Perry, C. & Faulds, D. (1996). Valaciclovir. Drugs 52, 754-72.
6. Fletcher, C. & Bean, B. (1985). Evaluation of oral aciclovir therapy. Drug Intelligence and Clinical Pharmacy 19, 518-24.
7. De Miranda, P. & Blum, M. (1983). Pharmacokinetics of aciclovir after intravenous and oral dosing. Journal of Antimicrobial Chemotherapy 12, Suppl. B, 29-37.
8. Zovirax prescribing information (2001). GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
9. Krasny, H., deMiranda, P., Blum, M. et al. (1981). Pharmacokinetics and bioavailability of aciclovir in the dog. Journal of Pharmacology and Experimental Therapeutics 261, 281-8.
10. Bacon, T., Levin, M., Leary, J. et al. (2003). Herpes simplex virus resistance to aciclovir and penciclovir after two decades of antiviral therapy. Clinical Microbiology Reviews 16, 114-28.
11. Purifoy, D., Beauchamp, L., de Miranda, P. et al. (1993). Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride and 882C, a specific agent for varicella. Journal of Medical Virology 41, Suppl. 1, 139-45.
12. Beauchamp, L., Orr, G., de Miranda, P. et al. (1992). Amino acid ester prodrugs of aciclovir. Antviral Chemistry and Chemotherapy 3, 157-64.
13. De Vrueh, R., Smith, P. & Lee, C. (1998). Transport of L-valine-aciclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. Journal of Pharmacology and Experimental Therapeutics 286, 1166-70.
14. Han, H., de Vreuh, R., Rhie, J. et al. (1998). 5′-amino acid esters of antiviral nucleosides, aciclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharmaceutical Research 15, 1154-9.
15. Han, H., Oh, D. & Amidon, G. (1998). Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharmaceutical Research 15, 1382-6.
16. Guo, A., Hu, P., Balimane, P. et al. (1999). Interactions of a non-peptidic drug, valaciclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. Journal of Pharmacology and Experimental Therapeutics 289, 448-54.
17. Balimane, P., Tamai, I., Guo, A. et al. (1998). Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valaciclovir. Biochemical and Biophysical Research Communications 250, 246-51.
18. Ganapathy, M., Huang, W., Wang, H. et al. (1998). Valaciclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochemical and Biophysical Research Communications 246, 470-5.
19. Phan, D., Chin-Hong, P., Lin, E. et al. (2003). Intra- and inter-individual variabilities of valaciclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Antimicrobial Agents and Chemotherapy 47, 2351-3.
20. Landowski, C., Sun, D., Foster, D. et al. (2003). Gene expression in the human intestine and correlation with oral valaciclovir pharmacokinetic parameters. Journal of Pharmacology and Experimental Therapeutics 306, 778-6.
21. Soul-Lawton, J., Seaber, E., On, N. et al. (1995). Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of aciclovir, following oral administration to humans. Antimicrobial Agents and Chemotherapy 39, 2759-64.
22. Weller, S., Blum, M., Doucette, M. et al. (1993). Pharmacokinetics of the aciclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clinical Pharmacology and Therapeutics 54, 595-605.
23. Burnette, T. & de Miranda, P. (1994). Metabolic disposition of the aciclovir prodrug valaciclovir in the rat. Drug Metabolism Disposition 22, 60-4.
24. Burnette, T., Harrington, J., Reardon, J. et al. (1995). Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of aciclovir. Journal of Biological Chemistry 270, 15827-31.
25. Laskin, O. (1983). Clinical pharmacokinetics of aciclovir. Clinical Pharmacokinetics 8, 187-201.
26. Jacobson, M., Gallant, J., Wang, L. et al. (1994). Phase I trial of valaciclovir, the L-valyl ester of aciclovir, in patients with advanced human immunodeficiency virus disease. Antimicrobial Agents and Chemotherapy 38, 1534-40.
27. Steingrimsdottir, H., Gruber, A., Palm, C. et al. (2000). Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrobial Agents and Chemotherapy 44, 270-9.
28. Wang, L., Schultz, M., Weller, S. et al. (1996). Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. Antimicrobial Agents and Chemotherapy 40, 80-5.
29. Elion, G., Furman, P., Fyfe, J. et al. (1977). Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl)guanine. Proceedings of the National Academy of Sciences, USA 74, 5716-20.
30. Beutner, K., Friedman, D., Forszpaniak, C. et al. (1995). Valaciclovir compared with aciclovir for improved therapy for herpes zoster in immunocompetent patients. Antimicrobial Agents and Chemotherapy 39, 1546-53.
31. Valtrex prescribing information. (2003). GlaxoSmithKline, Research Triangle Park, North Carolina, USA. http://us.gsk.com/assets/us_valtrex.pdf
32. Patel, R., Bodsworth, N., Woolley, P. et al. (1997). Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourinary Medicine 73, 105-9.
33. Corey, L., Wald, A., Patel, R. et al. (2004). Once-daily valaciclovir to reduce the risk of transmission of genital herpes. New England Journal of Medicine 350, 11-20.
34. Collin, J., Prisant, O., Cochener, B. et al. (2000). Comparison of the efficacy and safety of valaciclovir and aciclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 107, 1507-11.
35. Eisen, D., Essell, J., Sigmund, D. et al. (2003). Clinical utility of oral valaciclovir compared with oral aciclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplantation 31, 51-5.
36. Egan, J., Caroll, K., Yonan, N. et al. (2002). Valaciclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial. Journal of Heart and Lung Transplantation 21, 460-6.
37. Winston, D., Yeager, A., Chandrasekar, P. et al. (2003). Randomized comparison of oral valaciclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clinical Infectious Diseases 36, 749-758.